There is provided an ammoxidation catalyst for propylene having a structure in which molybdenum (Mo) oxide is supported first, and an oxide of heterogeneous metals including bismuth (Bi) is supported later. Related methods of making and using the catalyst are also provided.

There is provided an ammoxidation catalyst for propylene having a structure in which molybdenum (Mo) oxide is supported first, and an oxide of heterogeneous metals including bismuth (Bi) is supported later. Related methods of making and using the catalyst are also provided.

The present disclosure relates to an ammoxidation catalyst for propylene, a manufacturing method of the same, and an ammoxidation method of propylene using the same. Specifically, in one embodiment of the present disclosure, there is provided a catalyst having a structure in which a metal oxide is supported on a silica support having a narrow particle size distribution, and excellent wear resistance.

The present disclosure relates to an ammoxidation catalyst for propylene, a manufacturing method of the same, and an ammoxidation method of propylene using the same. Specifically, in one embodiment of the present disclosure, there is provided a catalyst having a structure in which a metal oxide is supported on a silica support having a narrow particle size distribution, and excellent wear resistance.

The present disclosure relates to an ammoxidation catalyst for propylene, a manufacturing method of the same, and an ammoxidation method of propylene using the same. Specifically, in one embodiment of the present disclosure, there is provided a catalyst having a structure in which a metal oxide is supported on a silica support having a narrow particle size distribution, and excellent wear resistance.

A catalytic composition useful for the conversion of an olefin selected from the group consisting of propylene, isobutylene or mixtures thereof, to acrylonitrile, methacrylonitrile, and mixtures thereof. The catalytic composition comprises a complex of metal oxides comprising rubidium, bismuth, cerium, molybdenum, iron and other promoters, with a desirable composition.

A catalytic composition useful for the conversion of an olefin selected from the group consisting of propylene, isobutylene or mixtures thereof, to acrylonitrile, methacrylonitrile, and mixtures thereof. The catalytic composition comprises a complex of metal oxides comprising rubidium, bismuth, cerium, molybdenum, iron and other promoters, with a desirable composition.

A catalytic composition useful for the conversion of an olefin selected from the group consisting of propylene, isobutylene or mixtures thereof, to acrylonitrile, methacrylonitrile, and mixtures thereof. The catalytic composition comprises a complex of metal oxides comprising rubidium, bismuth, cerium, molybdenum, iron and other promoters, with a desirable composition.

Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.

Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.